Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SSKN Stock Forecast 2026-2027
$0.19
Current Price
$1.13M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SSKN Price Targets
+5,584.2%
To High Target of $10.80
+5,584.2%
To Median Target of $10.80
+5,584.2%
To Low Target of $10.80
SSKN Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-92.0%
1 Year Change
-84.9%
Year-to-Date Change
-95.1%
From 52W High of $3.86
+5.6%
From 52W Low of $0.18
📊 TOP ANALYST CALLS
Did SSKN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Strata Skin is one of their latest high-conviction picks.
Latest SSKN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, SSKN has a bullish consensus with a median price target of $10.80 (ranging from $10.80 to $10.80). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.19, the median forecast implies a 5,584.2% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SSKN Analyst Ratings
1
Buy
0
Hold
0
Sell
SSKN Price Target Range
Low
$10.80
Average
$10.80
High
$10.80
Current: $0.19
Latest SSKN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SSKN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | Maxim Group | Anthony Vendetti | Buy | Initiates | $6.00 |
| May 16, 2023 | CG Capital | Rich Cockrell | Outperform | Reiterates | $4.00 |
| Nov 3, 2020 | HC Wainwright & Co. | Joseph Pantginis | Buy | Upgrade | $3.00 |
| Mar 17, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Dec 9, 2019 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Nov 21, 2019 | Oppenheimer | Outperform | Initiates | $N/A | |
| Dec 10, 2018 | Northland Capital Markets | Outperform | Initiates | $N/A | |
| Dec 10, 2018 | Northland Securities | Outperform | Initiates | $N/A |
Strata Skin Sciences Inc. (SSKN) Competitors
The following stocks are similar to Strata Skin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SSKN
Strata Skin
mkt cap
1.13M
Strata Skin Sciences Inc. (SSKN) Financial Data
Strata Skin Sciences Inc. has a market capitalization of $1.13M with a P/E ratio of -0.1x. The company generates $30.98M in trailing twelve-month revenue with a -35.1% profit margin.
Revenue growth is -21.2% quarter-over-quarter, while maintaining an operating margin of -26.8% and return on equity of -204.1%.
Valuation Metrics
Market Cap
$1.13M
Enterprise Value
$11.27M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
-21.2%
Gross Margin
+60.4%
Operating Margin
-26.8%
Net Margin
-35.1%
EPS Growth
-21.2%
Financial Health
Cash/Price Ratio
+632.6%
Current Ratio
0.9x
Debt/Equity
1,241.4x
ROE
-204.1%
ROA
-11.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Strata Skin Sciences Inc. (SSKN) Business Model
About Strata Skin Sciences Inc.
What They Do
Develops innovative dermatological treatment technologies.
Business Model
The company generates revenue by developing and commercializing medical technology products, primarily the XTRAC laser system, which offers non-invasive treatments for various skin disorders. By providing effective alternatives to traditional therapies, Strata Skin Sciences serves dermatology clinics and medical practices, thereby capturing a share of the growing market for advanced skin treatments.
Additional Information
Strata Skin Sciences is well-positioned in the healthcare sector, addressing the increasing demand for effective dermatological solutions. Through its commitment to innovation and improvement of treatment options, the company aims to enhance patient outcomes and quality of life for individuals with chronic skin conditions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
106
CEO
Dr. Dolev Rafaeli Ph.D.
Country
United States
IPO Year
2005
Website
www.strataskinsciences.comStrata Skin Sciences Inc. (SSKN) Latest News & Analysis
Latest News
Quick Summary
A study confirms that XTRAC® Excimer Laser combined with oral JAK inhibitors is more effective than tacrolimus for treating progressive vitiligo in children, suggesting growth in the market.
Why It Matters
The study's findings highlight a competitive advantage for the XTRAC® system, potentially increasing market share and revenue for the company, which is attractive for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clinical data, including a February 2026 study from Georgetown University, supports the use of optimized Excimer laser UVB strategies for treating inflammatory skin conditions.
Why It Matters
Positive clinical data on Excimer laser UVB treatments could boost healthcare stocks, attract investment in dermatological innovations, and enhance market confidence in emerging skin therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
STRATA Skin Sciences (Nasdaq: SSKN) announced that Johns Hopkins Dermatology will now use its XTRAC® 308 nm excimer laser in clinical treatments, enhancing its product reach.
Why It Matters
Johns Hopkins' addition of the XTRAC® 308 nm excimer laser enhances STRATA Skin Sciences' credibility and market reach, potentially boosting sales and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
STRATA Skin Sciences Confirms Nasdaq Delisting
3 months ago
Quick Summary
STRATA Skin Sciences, Inc. has filed a Form 25 to deregister its common stock, leading to suspension of trading on Nasdaq as of February 19, 2026. A Form 15 will follow to terminate further reporting obligations.
Why It Matters
STRATA Skin Sciences' move to deregister its stock and suspend trading signals potential financial instability, reducing transparency and possibly limiting investor confidence and liquidity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
STRATA Skin Sciences shares fell 8% despite a new meta-analysis showing up to 85% improvement in plaque psoriasis with its 308 nm excimer laser.
Why It Matters
STRATA Skin Sciences' stock drop indicates market skepticism about the new positive data, potentially affecting future growth and investor confidence in the company's product potential.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Laseroptek America Corp. has filed counterclaims against Strata Skin Sciences and CEO Dolev Rafaeli in an ongoing lawsuit initiated by Strata.
Why It Matters
Laseroptek America’s legal actions against Strata Skin Sciences could impact stock prices, investor sentiment, and market dynamics, depending on the outcome of the litigation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SSKN Stock
What is Strata Skin Sciences Inc.'s (SSKN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Strata Skin Sciences Inc. (SSKN) has a median price target of $10.80. The highest price target is $10.80 and the lowest is $10.80.
Is SSKN stock a good investment in 2026?
According to current analyst ratings, SSKN has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SSKN stock?
Wall Street analysts predict SSKN stock could reach $10.80 in the next 12 months. This represents a 5,584.2% increase from the current price of $0.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Strata Skin Sciences Inc.'s business model?
The company generates revenue by developing and commercializing medical technology products, primarily the XTRAC laser system, which offers non-invasive treatments for various skin disorders. By providing effective alternatives to traditional therapies, Strata Skin Sciences serves dermatology clinics and medical practices, thereby capturing a share of the growing market for advanced skin treatments.
What is the highest forecasted price for SSKN Strata Skin Sciences Inc.?
The highest price target for SSKN is $10.80 from at , which represents a 5,584.2% increase from the current price of $0.19.
What is the lowest forecasted price for SSKN Strata Skin Sciences Inc.?
The lowest price target for SSKN is $10.80 from at , which represents a 5,584.2% increase from the current price of $0.19.
What is the overall SSKN consensus from analysts for Strata Skin Sciences Inc.?
The overall analyst consensus for SSKN is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.80.
How accurate are SSKN stock price projections?
Stock price projections, including those for Strata Skin Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 6:48 PM UTC